Background 12
INTRODUCTION 37
In the present scenario, the debilitating nature of cardiovascular disorder is alarming and 38 needs a constant watch on the premature morbidity and mortality status. Cardiomyopathy 39 is the heart muscle disease and most common genetic disease of the heart, characterized 40
These types can be primary myocardial disorders or at times develop as a secondary 48 consequence of a variety of conditions viz., myocardial ischemia, inflammation, viral 49 infection, increased myocardial pressure or volume load, and toxic agents (4). The 50 etiology of both HCM and DCM involve cardiac energy imbalances and the clinical 51 expressions of them are based on the addictive factors that are involved in it. 52
53
The prevalence of the dilated cardiomyopathy has formerly been estimated 54 at 36.5/100,000, with an incidence of 4-8/100,000 persons-year (5). An 55 echocardiographic analysis of 4111 subjects in CARDIA study by (6) revealed 56 hypertrophic cardiomyopathy affects 1 in 500 people, a prevalence similar to familial 57 hypercholesterolemia. Recent study estimates prevalence of dilated and hypertrophic 58 Cardiomyopathy as 36 cases per 100,000 people and 10-20 cases per 100,000 people 59 respectively (7). Most of the dilated Cardiomyopathy cases are sporadic; although 20-60 35% of them are familial (8). The incidence of dilated cardiomyopathy varies in men and 61 women. However, in general, heart failure is more common in men (9). The treatment 62 arm of the Studies on Left Ventricular Dysfunction (SOLVD), in which only 15% of the 63 4 patients were women, reported no sex-related difference in survival in either the placebo 64 group or the Enalapril group (10, 11) . Age distribution depends on prognosis, diagnosis 65 or onset of any underlying disease. However, advancing age is reported as an 66 independent risk factor for mortality in several studies (12) . 67
Phospholamban (PLN) is a small transmembrane phosphoprotein of 52 amino acids that 68 plays an important role in cardiac contraction and relaxation. Phospholamban, expressed 69 in the sarcoplasmic reticulum membrane controls cellular calcium levels by a mechanism 70 that depends on its phosphorylation (13). The human ventricle and quadriceps displayed 71 high levels of phospholamban transcripts and proteins (14), whereas lower expression in 72 smooth muscles and right atrium. DCM patients with a phospholamban gene mutation 73 have a chronically inhibited Ca2+-ATPases pump, which leads to DCM in their teenage 74 (15, 16) . 75
Susceptibility genes have a role in the development of cardiomyopathies, whereas 76 modifier genes have a role in the evolution or prognosis of the disease. In most studies 77 due to limited sample sizes, the role of susceptibility and modifier genes have been only 78 suggestive (17). Various genes underlying cardiomyopathy have been identified from 79 linkage as well as candidate gene studies, and include those coding for proteins involved 80 in the cytoskeleton, the Z-disk, the nuclear envelop, ion conduction and calcium handling 81 proteins (18). This variability in expression of these causal genes is also seen among 82 family members sharing the same mutation. This variable expressivity, which confuses 83 genotype/phenotype correlations, could be partially explained by both environmental 84 influences and genetic modifiers (19). The angiotensin-1-converting enzyme (ACE) 85 polymorphism has been commonly studied with variable results. It's noteworthy to study 86 5 and understand the importance of modifier genes. The genetic polymorphisms of the 87 renin-angiotensin-aldosterone system (RAAS) are found to influence the progression to 88 cardiac disorders (20 
GENETIC ANALYSIS 150
In the present study, the index cases are categorized into two groups viz., familial case 151
showing the incidence of the disease in first and second-degree relatives and in sporadic 152 cases lack of any familial incidence, presumably non-genetic in origin. The present study 153 examined a comprehensive screening of Phospholamban and a key determinant/modifier 154 angiotensin-1-converting enzyme gene polymorphism. 155
156

DNA ISOLATION and QUANTIFICATION 157
Genomic DNA was extracted from the peripheral blood following the 158 protocol of (23). Briefly, the collected blood was mixed with an equal volume of TKM1 159 buffer (10mM Tris-HCl, 10mM KCl,10mM MgCl 2 and 2mM EDTA) and 100 μl Triton X. 160
The contents were centrifuged and the pellet was washed with TKM1 repeatedly until the 161 cell debris is washed out. The pellet is suspended in 800 μl of TKM2 solution (10mM Tris-162
HCl,10mM KCl, 10mM MgCl 2 , 2mM EDTA and 0.4M NaCl) followed by centrifugation and 163 precipitation of the supernatant in ethanol. The DNA samples were then stored at -20°C 164 for subsequent analyses. The DNA was quantified using spectrophotometer. The DNA 165 was diluted in TE to yield 50ng/μl concentration. 166
167
PHOSPHOLAMBAN (PLN) POLYMERASE CHAIN REACTION 168
The primers of the hotspots exons of Phospholamban (PLN) forward primer 5'-169 tatttttctcataattaaaattcctgc-3' and reverse primer 5'-aaagtaagaattaccaaagtcagcg-3' for 170
Exon 1 and forward primer 5'-aacaatagtgctgaggaagatgaa-3' and reverse primer 5'-171 ttgttttcctgtctgcatgg-3' for Exon 2 were used (24). 
RESULTS
214
EPIDEMIOLOGICAL STUDY 215
Patients and Baseline Characteristics 216
A total of 109 unrelated index patients who have echocardiographically and 217 electrocardiographically assessed for cardiomyopathy and 100 aged matched control 218 subjects were studied. About 73 percent of the patients had dilated cardiomyopathy and 219 27 percent hypertrophic cardiomyopathy. Details on age, body mass index, blood 220 pressure, blood biochemical profile, associated clinical and non-clinical features of the 221 patients, control subjects were given in (Table 1) . Males were significantly higher among 222 the patients (73%). The mean age of all patients was 37.22 ± 12.43 years. Occurrence 223 was familial in 24% of cases, but sporadic in the other 76% of patients. In patients group 224 about 30% of them had family history of sudden cardiac death and 14% of them showed 225 parental consanguinity. Mean value of body mass index and body surface area was same 226 in patients and control (p=0.085, p=0.515). 227 228
Hemodynamic and Biochemical Parameters 229
Diastolic blood pressure, heart rate and systolic blood pressure of cardiomyopathy 230 patients was extremely significant when compared with the control subjects (p<0.05). 231
Cardiomyopathy patients were characterized with high atrial natriuretic peptide (ANP) and 232 brain natriuretic peptide (BNP) level (p<0.001). Contrastingly creatinine phosphokinase 233 (CpK), serum aspartate transaminase (SGOT), serum alanine transaminase (SGPT), 234 glucose, urea and creatinine levels did not show much variation between patients and 235 control group (Table 1) . Similarly, co-morbid factors such as diabetes, obesity, smoking 236 and alcoholism did not show any influence on patient population. 237
238
CLINICAL CHARACTERISTICS 239
The electrocardiographic and echocardiographic characteristics of the cardiomyopathic 240 patients and control group were given in 
MOLECULAR ASPECTS 248
Phospholamban Gene Mutation 249
Phospholamban gene is located on chromosome 6q22.1. Genomic sequence of the gene 250 is 12146 bps nucleotides long which encodes 1742 bps mRNA coding region comprises 251 159 bps which encodes 2exons. The protein is a pentamer and is a major substrate for 252 cAMP-dependent protein kinase in the cardiac muscle. The protein inhibits Ca2+-ATPase 253 in unphosphorylated state. The protein is a key regulator of cardiac diastolic function. 254 Table 3 shows the detailed description of the mutations in phospholamban gene. Seven 255 mutations -two in the 5' flanking region, two in exon 1 and three in the intron1 region 256 (Figure 1 (a-f) ). Transition T/G in 4887 nucleotide regions of 5' flanking region was 257 observed in two HCM probands with four affected family members and also in one dilated 258 cardiomyopathic proband with no affected relatives. 15511-15512 insertion T was 259 observed in one dilated cardiomyopathic proband with 2 affected family members and 260 one dilated cardiomyopathic proband with no affected family members. 261 262
Description of Familial Condition 263
4887(T/G) mutation: 264
In the pedigree of the H9 proband (male, 21years) (Figure 2 ), the proband's father and 265 his two uncles died young of sudden cardiac arrest. The younger brother of the proband's 266 father has an affected son. The mutation was in heterozygotic state and it is not observed 267 in unaffected. 268
In the pedigree of H10 proband (Figure 3) , the T to G transition was observed in two 269 family members The H10 proband (Male, age: 41years) had an affected offspring who 270 was deceased subsequently to this study. The proband's parents are consanguineous 271 and his mother died of cardiac arrest. The proband's brother had also carried this mutation 272 and his daughter died unexpectedly at the age of 18 years. 273
ins T mutation: 274
The intronic mutation in PLN gene was observed in one dilated cardiomyopathy patient 275 and in his family members (Figure 4) . The D15 proband (Male, age: 37 years) who carried 276 this mutation has an affected father (66 years). The proband's father's brother died of 277 sudden cardiac arrest at the age of 22 years. The mutation in their family members were 278 in heterozygotic state and not found in unaffected. 287-basepair sequence of DNA in intron 16 of this modifier gene, encoding for ACE with 290 differences in plasma ACE levels is examined in Cardiomyopathy patients (29). Table 4  291 illustrates variation in the genotype and allele frequency of the patient and control. Most 292 notably the deletion homozygotes found to be higher in the patients. Also, the percent of 293 heterozygote varied significantly among the two groups. Similarly, the deletion allele 294 frequency was considerably higher in patients about 60% than controls (44%). The chi 295 square value in patients and controls was 0.109 and 1.148 respectively. 296
The genotypes DD vs ID, DD vs II, ID vs II, DD + ID vs II, DD vs ID + II and D vs I was 297 taken for the odds ratio comparison. All the odds ratio values were higher than the 298 threshold value of 1. The odds ratio was highest for the genotype DD vs II (3.82) with a 299 χ2 value of 10.59. This was followed by DD + ID vs II and ID vs II genotypes having an 300 odds ratio of 2.79 (χ2 =8.60) and 2.27 (χ2=4.48) respectively. The DD vs ID genotype 301 comparison had an odds ratio of 0.60 (χ2 =1.94). It should be noted that the χ2 value is 302 taken to evaluate the significance of the genotypes. Patients with D allele tend to be a 303 higher risk and modify the disease pattern when compared with I allele. The odds ratio 304 was found out to be 1.14 with a χ2 value 12.09. In Table 5 Cardiomyopathies are diseases of the heart muscle and a cause of concern. They exhibit 312 a wide spectrum in disease onset, manifestation as well as in progression (30). Significant 313 differences were observed for age and sex ratio between control and patients with 314 cardiomyopathy. Mean age of diagnosis was higher in the patient data of the present 315 study than in studies of HCM and DCM previously reported (31, 32) . This may be due to 316 mutation carriers screened in a predictive setting represent an asymptomatic subgroup 317 within the total population of affected. Besides age, gender was an important cofactor in 318 the clinical manifestation of HCM and DCM (33). The cardiomyopathy patients of the 319 present study were characterized with significant increase in atrial natriuretic peptide and 320 brain natriuretic peptide, which were correlated with left ventricular ejection fraction, mean 321 pulmonary arterial pressure and pulmonary artery wedge pressure. Present data provides 322 evidence that ANP and BNP are the best indicators for heart failure in cardiomyopathy 323
patients. An elevated mean diastolic blood pressure (81.41 ± 4.76) and systolic blood 324 pressure (125.0 ± 9.17) were observed in cardiomyopathy patient's data of the present 325 study. A higher diastolic and systolic blood pressure has been observed in Caucasians 326 
cardiomyopathy. 342
The mutation that is located near the promoter region has been defined as the fragment 343 with maximal transcriptional activity (44). The increase or the decrease in phospholamban 344 activity due to the disruption around the promoter region can lead to cardiomyopathy (41). 345
Some carriers do not exhibit clinical conditions and mutation may be due to other genetic 346 and environmental factors. This study concludes that PLN gene mutations are not 347 frequent cause of hypertrophic or dilated cardiomyopathy in Indian population. 348
Although similar data were lacking, it was observed that Indians show a greater variation 349 and this may be due to the polymorphism in ACE gene (modifier gene). genotype was also found to be associated with hypertension, restenosis, diabetes and 367 myocardial infarction (51,52). However, absences of association (53,54) or influencing 368 the cardiac phenotype (55) were reported in few other studies. These variations were 369 partly accounted for ethnicity of the patients and to the sampling of the patients (56, 57) . 370
371
CONCLUSION: 372
Among the two types of cardiomyopathies; dilated cardiomyopathy (73%) was found to 373 be most predominant, whereas hypertrophic cardiomyopathy accounts for 27%. In 374 general, increased male predominance (73%) was observed in both the types of 375 cardiomyopathies. Familial occurrence was in 24% of the patients, parental consanguinity 376 was 14% and 30% had family history of sudden cardiac death. Diastolic blood pressure 377 of the cardiomyopathy patients was significant (p<0.05) than the systolic blood pressure 378 and heart rate. Also, they were characterized with higher Atrial Natriuretic Peptide and The increase or decrease in phospholamban activity due to the disruption around the 392 promoter region can lead to cardiomyopathy. No mutations were observed in control 393 subjects. Further, the deletion allele frequency of angiotensin-1-converting enzyme was 394 considerably higher in cardiomyopathy patients (61.5%) than the control subjects (44%). 395
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LVESD(mm)
46.0 ± 6*** 26 ± 7*** 31 ± 5 LVEDD(mm) 71.5 ± 2*** 69 ± 7*** 52 ± 3 LVEF (%) 65 ± 6*** 36 ± 7*** 53 ± 7 FS (%) 39 ± 7** 38 ± 8 36 ± 7
IVST(mm) 18 ± 6*** 11 ± 3*** 8 ± 2 The present study investigates the association of spectrum of clinical symptoms and the 627 epidemiological variables like age, sex, familial status, and parental consanguinity. The 628 current study also evaluates Angiotensin-1-Converting Enzyme gene polymorphism and 629 its role as a marker / modifier in Cardiomyopathy. 
